Pages that link to "Q34371637"
Jump to navigation
Jump to search
The following pages link to Very mild muscular dystrophy associated with the deletion of 46% of dystrophin (Q34371637):
Displaying 50 items.
- The binding protein for globular heads of complement C1q, gC1qR. Functional expression and characterization as a novel vitronectin binding factor (Q24317721) (← links)
- Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications (Q24682555) (← links)
- Recent advances in innovative therapeutic approaches for Duchenne muscular dystrophy: from discovery to clinical trials (Q26741409) (← links)
- The emerging role of viral vectors as vehicles for DMD gene editing (Q26746647) (← links)
- Dystrophin and the two related genetic diseases, Duchenne and Becker muscular dystrophies (Q26795772) (← links)
- Thyroid hormones and skeletal muscle--new insights and potential implications (Q26991631) (← links)
- The Crystal Structures of Dystrophin and Utrophin Spectrin Repeats: Implications for Domain Boundaries (Q27671652) (← links)
- Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy (Q28084979) (← links)
- Primary structure of dystrophin-related protein (Q28183558) (← links)
- Genetic therapies for RNA mis-splicing diseases (Q28235690) (← links)
- Targeted skipping of human dystrophin exons in transgenic mouse model systemically for antisense drug development (Q28478166) (← links)
- The Dystrophin Complex: Structure, Function, and Implications for Therapy (Q30376293) (← links)
- DMD Mutations in 576 Dystrophinopathy Families: A Step Forward in Genotype-Phenotype Correlations (Q30378068) (← links)
- Correlation of muscle fiber type measurements with clinical and molecular genetic data in Duchenne muscular dystrophy (Q30578546) (← links)
- CRISPR-mediated Genome Editing Restores Dystrophin Expression and Function in mdx Mice (Q30725695) (← links)
- Rapid mapping by transposon mutagenesis of epitopes on the muscular dystrophy protein, dystrophin (Q33267865) (← links)
- Screening for mutations in the muscle promoter region and for exonic deletions in a series of 115 DMD and BMD patients (Q33593754) (← links)
- Predicted and observed sizes of dystrophin in some patients with gene deletions that disrupt the open reading frame (Q33594782) (← links)
- Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 1. Trends across the clinical groups (Q33595755) (← links)
- Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients (Q33595762) (← links)
- Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 3. Differential diagnosis and prognosis (Q33595768) (← links)
- Becker muscular dystrophy patient with a large intragenic dystrophin deletion: implications for functional minigenes and gene therapy (Q33597923) (← links)
- Lentiviral vectors can be used for full-length dystrophin gene therapy (Q33668822) (← links)
- Truncated dystrophins can influence neuromuscular synapse structure. (Q33676836) (← links)
- Therapy of Genetic Disorders-Novel Therapies for Duchenne Muscular Dystrophy (Q33678893) (← links)
- Octa-guanidine morpholino restores dystrophin expression in cardiac and skeletal muscles and ameliorates pathology in dystrophic mdx mice (Q33713525) (← links)
- Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles (Q33715654) (← links)
- Muscle structure influences utrophin expression in mdx mice. (Q33747602) (← links)
- Full-length dystrophin reconstitution with adeno-associated viral vectors (Q33782799) (← links)
- Emerging genetic therapies to treat Duchenne muscular dystrophy (Q33796975) (← links)
- Gene and cell-mediated therapies for muscular dystrophy. (Q33831193) (← links)
- Understanding dystrophinopathies: an inventory of the structural and functional consequences of the absence of dystrophin in muscles of the mdx mouse (Q33836366) (← links)
- Dystrophin and utrophin: genetic analyses of their role in skeletal muscle (Q33840935) (← links)
- Prospects for gene therapy for inherited cardiomyopathies (Q34103468) (← links)
- Meganucleases can restore the reading frame of a mutated dystrophin (Q34110253) (← links)
- Immunohistochemical analysis of dystrophin-associated proteins in Becker/Duchenne muscular dystrophy with huge in-frame deletions in the NH2-terminal and rod domains of dystrophin (Q34119276) (← links)
- Optimizing exon skipping therapies for DMD. (Q34171630) (← links)
- Advances in Duchenne muscular dystrophy gene therapy (Q34267400) (← links)
- Dystrophin and mutations: one gene, several proteins, multiple phenotypes (Q34278933) (← links)
- Personalized exon skipping strategies to address clustered non-deletion dystrophin mutations (Q34349200) (← links)
- A phase 1/2a follistatin gene therapy trial for becker muscular dystrophy. (Q34443876) (← links)
- Gene therapy of mdx mice with large truncated dystrophins generated by recombination using rAAV6. (Q34473295) (← links)
- Physiological characterization of muscle strength with variable levels of dystrophin restoration in mdx mice following local antisense therapy. (Q34473309) (← links)
- Chronic systemic therapy with low-dose morpholino oligomers ameliorates the pathology and normalizes locomotor behavior in mdx mice (Q34556906) (← links)
- Our trails and trials in the subsarcolemmal cytoskeleton network and muscular dystrophy researches in the dystrophin era (Q34567946) (← links)
- Phosphorylation within the cysteine-rich region of dystrophin enhances its association with β-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting (Q34575694) (← links)
- Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse (Q34582428) (← links)
- The influence of antisense oligonucleotide length on dystrophin exon skipping. (Q34590393) (← links)
- One-year treatment of morpholino antisense oligomer improves skeletal and cardiac muscle functions in dystrophic mdx mice (Q34621772) (← links)
- Gene therapy for muscular dystrophy: moving the field forward (Q34625436) (← links)